ZA200800228B - Nucleotide analogue prodrug and the preparation thereof - Google Patents
Nucleotide analogue prodrug and the preparation thereofInfo
- Publication number
- ZA200800228B ZA200800228B ZA200800228A ZA200800228A ZA200800228B ZA 200800228 B ZA200800228 B ZA 200800228B ZA 200800228 A ZA200800228 A ZA 200800228A ZA 200800228 A ZA200800228 A ZA 200800228A ZA 200800228 B ZA200800228 B ZA 200800228B
- Authority
- ZA
- South Africa
- Prior art keywords
- preparation
- nucleotide analogue
- analogue prodrug
- prodrug
- nucleotide
- Prior art date
Links
- 125000003729 nucleotide group Chemical group 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510040480 | 2005-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200800228B true ZA200800228B (en) | 2008-09-25 |
Family
ID=37531955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200800228A ZA200800228B (en) | 2005-06-13 | 2008-01-09 | Nucleotide analogue prodrug and the preparation thereof |
Country Status (5)
Country | Link |
---|---|
US (1) | US20100216822A1 (zh) |
JP (1) | JP5323476B2 (zh) |
CN (5) | CN102240295B (zh) |
WO (1) | WO2006133632A1 (zh) |
ZA (1) | ZA200800228B (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011111074A2 (en) * | 2010-03-11 | 2011-09-15 | Matrix Laboratories Ltd | An improved process for the preparation of tenofovir disoproxil fumarate |
US9187508B2 (en) | 2010-08-01 | 2015-11-17 | Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. | Crystalline forms of tenofovir dipivoxil fumarate |
CN102453055B (zh) * | 2010-10-29 | 2015-04-01 | 上海迪赛诺医药发展有限公司 | 制备(r)-9-(2-膦酰甲氧基丙基)腺嘌呤双(异丙氧羰基氧甲基)酯的方法 |
EP2697238B1 (en) * | 2011-04-08 | 2019-03-20 | Laurus Labs Limited | Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof |
CN103374038B (zh) * | 2012-04-11 | 2016-04-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种抗病毒药物的制备方法 |
CN103626803B (zh) * | 2012-08-23 | 2017-12-15 | 四川海思科制药有限公司 | 替诺福韦二吡呋酯的固体及其制备方法和用途 |
CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
WO2014068265A1 (en) * | 2012-10-29 | 2014-05-08 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
CN104725423A (zh) * | 2013-12-18 | 2015-06-24 | 山东新时代药业有限公司 | 一种富马酸替诺福韦二吡呋酯的合成方法 |
KR101548724B1 (ko) * | 2014-04-25 | 2015-09-02 | 주식회사 휴온스 | 고체 형태의 항바이러스제 및 이의 제조방법 |
CN105399771B (zh) * | 2014-07-21 | 2020-11-24 | 江苏豪森药业集团有限公司 | 替诺福韦前药晶型及其制备方法和用途 |
CN107334772B (zh) * | 2016-07-15 | 2020-02-14 | 安徽贝克生物制药有限公司 | 一种抗逆转录病毒药物组合物 |
CN107266500B (zh) * | 2017-08-10 | 2019-04-12 | 黄哲敏 | 一种泰诺福韦生产线的晶体析出反应系统 |
CN110577555A (zh) * | 2018-06-08 | 2019-12-17 | 欣凯医药化工中间体(上海)有限公司 | 一种无定形的替诺福韦十八烷氧乙酯的制备方法及其应用 |
WO2024033632A1 (en) * | 2022-08-08 | 2024-02-15 | Cipla Limited | An improved process for preparing antiviral phosphonate analogues |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2261619C (en) * | 1996-07-26 | 2006-05-23 | Gilead Sciences, Inc. | Nucleotide analogs |
PT1256585E (pt) * | 1997-07-25 | 2005-01-31 | Gilead Sciences Inc | Processo para a preparacao de 9-(2-(dietilfosfonometoxi)-etil)-adenina |
ZA986614B (en) * | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
CN1374314A (zh) * | 2002-03-13 | 2002-10-16 | 上海仲夏化学有限公司 | 阿德福韦酯无定形固化物及制备方法 |
CN1465582A (zh) * | 2002-07-01 | 2004-01-07 | 中国人民解放军军事医学科学院放射医 | 核苷酸类似物、含它的药物组合物及其用途 |
CN100488970C (zh) * | 2002-07-08 | 2009-05-20 | 江苏正大天晴药业股份有限公司 | 匹伏阿德福韦的晶型 |
CN100384426C (zh) * | 2003-12-05 | 2008-04-30 | 天津药物研究院 | 一种含活性成分阿德福韦或其盐的固体分散物及其制备方法 |
CN1679596B (zh) * | 2005-01-18 | 2010-12-08 | 美德(江西)生物科技有限公司 | 无结晶型态的阿地福韦酯与辅料的分散组合物及其制备方法 |
-
2006
- 2006-06-09 CN CN2011101429468A patent/CN102240295B/zh not_active Expired - Fee Related
- 2006-06-09 JP JP2008516109A patent/JP5323476B2/ja not_active Expired - Fee Related
- 2006-06-09 CN CN2011101429275A patent/CN102228464B/zh not_active Expired - Fee Related
- 2006-06-09 CN CN2011101429504A patent/CN102240297B/zh not_active Expired - Fee Related
- 2006-06-09 US US11/917,396 patent/US20100216822A1/en not_active Abandoned
- 2006-06-09 CN CN2011101429010A patent/CN102228463B/zh not_active Expired - Fee Related
- 2006-06-09 WO PCT/CN2006/001269 patent/WO2006133632A1/zh active Application Filing
- 2006-06-09 CN CN2011101429487A patent/CN102240296B/zh not_active Expired - Fee Related
-
2008
- 2008-01-09 ZA ZA200800228A patent/ZA200800228B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN102240295A (zh) | 2011-11-16 |
CN102240297B (zh) | 2013-04-03 |
CN102240295B (zh) | 2013-04-03 |
JP2008545802A (ja) | 2008-12-18 |
CN102228464B (zh) | 2013-06-05 |
WO2006133632A1 (fr) | 2006-12-21 |
US20100216822A1 (en) | 2010-08-26 |
CN102240297A (zh) | 2011-11-16 |
CN102228463B (zh) | 2012-12-19 |
JP5323476B2 (ja) | 2013-10-23 |
CN102228464A (zh) | 2011-11-02 |
CN102228463A (zh) | 2011-11-02 |
CN102240296A (zh) | 2011-11-16 |
CN102240296B (zh) | 2013-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200800228B (en) | Nucleotide analogue prodrug and the preparation thereof | |
GB2424581B (en) | Formulations | |
IL191791A0 (en) | Hcv prodrug formulation | |
EP1885665A4 (en) | FORMULATIONS OF DITHIOCARBAMATES AND PHOSPHITE | |
ZA200707654B (en) | Formulations | |
IL184834A0 (en) | Compositions and methods for the manufacture thereof | |
IL185258A0 (en) | Formulation with anti-tumor action | |
GB0507114D0 (en) | No 1 timemachine | |
GB0502992D0 (en) | The ballcaster | |
GB0509703D0 (en) | Hayfit 2 | |
IL189698A0 (en) | Thiomorpholine derivatives and processes for the preparation thereof | |
GB0514559D0 (en) | Qmaster 2005 | |
GB0511610D0 (en) | The motor-roll-off | |
GB0522821D0 (en) | Basemaster uk/4 | |
GB0514993D0 (en) | The ultimate Bar-B | |
GB0519041D0 (en) | Rollec 2 | |
GB0512635D0 (en) | iCorcost 7 | |
GB0517586D0 (en) | Corcost 6 | |
GB0522647D0 (en) | Nan 1 | |
GB0517452D0 (en) | iCorcost 5 | |
GB0520322D0 (en) | Webhead 2 | |
GB0616698D0 (en) | Ladderfix 2 | |
GB0518747D0 (en) | Zcdemo 14/9/05 | |
GB0515197D0 (en) | Freshbox 100 | |
GB0515077D0 (en) | iCorcost 9 |